GLP-1 drugs do not fit every patient
Last reviewed: 18 Jun 2026 Sources Wegovy tablet, emc [accessed 18 June 2026] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet [accessed 10 June 2026] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, The New England Journal of Medicine [accessed 10 June 2026] Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen, emc [accessed 10 June 2026] Wegovy 1.5 mg tablets SmPC/PIL, emc [accessed 18 June 2026] Related weight loss treatments Further reading on Wegovy pill Trusted by thousands Your health guided by experts Our doctors are regulated by the CQC and GPhC, the same bodies overseeing NHS care.
Peptides containing oxidation-sensitive residues like methionine or cysteine may have somewhat shorter refrigerated shelf lives
Their approach leans more towards optimizing existing, well-researched ingredients
No electrical impulses transmit effectively from the atria to the ventricles